natgillin/translations-raw huggingface dataset:
In the studies of acute coronary syndrome, all of the patients also took aspirin and the main measure of effectiveness was the number of patients experienced an ‘event’ such as a blocked artery, another heart attack or death during the study.
V študijah akutnega koronarnega sindroma so vsi bolniki jemali tudi aspirin, glavno merilo učinkovitosti pa je bilo število bolnikov z „dogodkom“, kot je blokirana arterija, še en srčni napad ali smrt med samo študijo.
In the studies of acute coronary syndrome, all of the patients also took aspirin and the main measure of effectiveness was the number of patients who experienced an ‘event’ such as a blocked artery, another heart attack or death during the study.
V študijah akutnega koronarnega sindroma so vsi bolniki jemali aspirin, glavno merilo učinkovitosti pa je bilo število bolnikov z „dogodkom“, kot je blokirana arterija, ponovni srčni napad ali smrt med samo študijo.
In the studies of acute coronary syndrome, all of the patients also took aspirin and the main measure of effectiveness was the number of patients who experienced an ‘event’ such as a blocked artery, another heart attack or death during the study.
V študijah akutnega koronarnega sindroma so vsi bolniki jemali aspirin, glavno merilo učinkovitosti pa je bilo število bolnikov z „dogodkom“, kot je zamašena arterija, ponovni srčni napad ali smrt med samo študijo.
In the studies of acute coronary syndrome, all of the patients also took aspirin and the main measure of effectiveness was the number of patients who experienced an ‘event’ such as a blocked artery, another heart attack or death during the study.
V študijah akutnega koronarnega sindroma so vsi bolniki jemali tudi aspirin, glavno merilo učinkovitosti pa je bilo število bolnikov z „dogodkom“, kot je blokirana arterija, ponovni srčni napad ali smrt med študijo.
In the studies of Invirase in combination with ritonavir, Invirase was as effective as indinavir, but more effective than lopinavir in reducing the viral load to less than 50 copies/ml.
V študijah, v katerih so zdravilo Invirase proučevali v kombinaciji z ritonavirjem, je bilo zdravilo Invirase pri zmanjševanju virusnega bremena na manj kot 50 kopij/ml enako učinkovito kot indinavir, a učinkoviteljše od lopinavirja.
In the studies of patients with BH4 deficiency, patients showed an improvement in blood phenylalanine levels and other markers of the disease when they were taking sapropterin dihydrochloride.
V študijah, ki so vključevale bolnike s pomanjkanjem BH4, so se pri osebah, ki so jemale sapropterinijev dihidroklorid, izboljšale ravni fenilalanina v krvi in drugi označevalci bolezni.
In the studies of PI-experienced patients, APV30003 and its extension, APV30005 (fosamprenavir 700 mg / ritonavir 100 mg twice daily: n=107), the following mutations emerged in patients experiencing virological failure through 96 weeks: L10F/I, L24I, V32I, L33F, M36I, M46I/L, I47V, I50V, I54L/M/S, A71I/T/V, G73S, V82A, I84V, and L90M.
V študijah bolnikov, ki so že bili zdravljeni z zaviralci proteaz, APV30003 in njenem podaljšku, APV30005 (fosamprenavir 700 mg / ritonavir 100 mg dvakrat na dan: n=107), so se pri bolnikih z virusnim neodzivom med 96 tedni zdravljenja pojavile naslednje mutacije: L10F/I, L24I, V32I, L33F, M36I, M46I/L, I47V, I50V, I54L/M/S, A71I/T/V, G73/S, V82A, I84Vin L90M.
In the studies of skin and soft tissue infections in adults, the success rates at seven to 12 days after the last injection of Cubicin were 67% in one study and 85% in the other.
V študijah okužb kože in mehkih tkiv pri odraslih je bila stopnja uspešnega kliničnega odziva od sedem do 12 dni po zadnji injekciji zdravila Cubicin v eni študiji 67 %, v drugi pa 85 %.
In the studies of treatment-naïve adults, ritonavir-boosted Telzir was as effective as the comparator medicines, but it was less effective in adults who had been treated before.
V študijah pri odraslih, ki se še niso zdravili, je bilo z ritonavirjem ojačano zdravilo Telzir enako učinkovito kot primerjalna zdravila, vendar je bilo pri odraslih, ki so se zaradi okužbe z virusom HIV že zdravili, manj učinkovito.
In the studies, images obtained in 45 healthy volunteers were compared with those obtained in 180 patients with Parkinson’s disease or related diseases, and in 29 patients with essential tremor.
V študijah so slike, dobljene pri 45 zdravih prostovoljcih, primerjali s tistimi, dobljenimi pri 180 bolnikih s Parkinsonovo boleznijo ali povezanimi obolenji, ter pri 29 bolnikih z esencialnim tremorjem.
In the studies, SevoFlo was equally effective when compared to other anaesthetic agents.
V študijah je bilo zdravilo SevoFlo enako učinkovito kot drugi anestetiki.
In the study carried out during an epidemic, 1% of the people taking Tamiflu developed flu after contact, compared with 5% of those taking placebo.
V študiji, izvedeni med epidemijo, je 1 % ljudi, ki so jemali zdravilo Tamiflu, po stiku z okuženim zbolelo za gripo, v primerjavi s 5 % tistih, ki so prejemali placebo.
In the study comparing Eliquis with warfarin, 1.3 % of the patients taking Eliquis had a stroke or clotting event every year compared with 1.6% of the patients taking warfarin.
V študiji, v kateri so zdravilo Eliquis primerjali z varfarinom, je 1,3 % bolnikov, ki so prejemali zdravilo Eliquis doživelo kap ali imelo krvni strdek vsako leto, v primerjavi z 1,6 % bolnikov, ki so jemali varfarin.
In the study comparing Incruse with tiotropium, FEV1 improvements over 24 weeks were similar for both medicines.
V študiji, v kateri so zdravilo Incruse primerjali s tiotropijem, so bila izboljšanja FEV1 v obdobju 24 tednov podobna pri obeh zdravilih.
In the study in adults, 62.8% (27 out of 43) of patients who received Revestive responded to treatment, compared with 30.2% (13 out of 43) who received placebo.
V študiji pri odraslih se je na zdravljenje odzvalo 62,8 % (27 od 43) bolnikov, ki so prejemali zdravilo Revestive, v primerjavi s 30,2 % (13 od 43) bolnikov, ki so prejemali placebo.
In the study in children aged 2 to 5 years, Kalydeco granules had a positive effect on bodyweight and the amount of chloride contained in sweat.
Študija pri otrocih, starih od dve do pet let , je pokazala pozitiven učinek zrnc zdravila Kalydeco na telesno maso in količino klorida v znoju.
In the study in children aged 4 weeks to 2 years Isentress treatment led to a reduction in viral load and after 48 weeks 53% of the children had viral loads below 50 copies/ml.
V študiji, izvedeni pri otrocih, starih od štiri tedne do dveh let, je zaradi zdravljenja z zdravilom Isentress prišlo do zmanjšanja virusnega bremena, saj je po 48 tednih 53 % otrok imelo virusno breme pod 50 kopijami/ml.
In the study in children and adolescents, Abilify was also more effective than placebo at reducing the manic symptoms of bipolar disorder.
V študiji pri otrocih in mladostnikih je bilo zdravilo pri zmanjševanju maničnih simptomov bipolarne motnje prav tako učinkovitejše od placebo.
In the study in children with skin and soft tissue infections, 88% of the patients receiving Cubicin (227 out of 257) and 86% of the patients receiving standard treatment (114 out of 132) were treated successfully.
V študiji pri otrocih z okužbami kože in mehkih tkiv je bilo 88 % (227 od 257) bolnikov, ki so prejemali zdravilo Cubicin, uspešno ozdravljenih, v primerjavi s 86 % (114 od 132) bolnikov, ki so prejemali standardno zdravljenje.
In the study in children, six out of seven patients did not need any transfusion of red blood cell and haemoglobin levels improved during treatment with Soliris.
V študiji pri otrocih šest od sedmih bolnikov med zdravljenjem z zdravilom Soliris ni potrebovalo nobene transfuzije rdečih krvnih celic, raven hemoglobina pa se je izboljšala.
In the study in children/adolescents aged 1 – 18 years with de novo ALL (study MC-ASP.5/ALL), by day 33 of induction treatment 10 patients in the Spectrila group (10.3 %) and 9 in the reference group (8.9 %) were measured positive for anti-asparaginase antibodies at least at one time point.
V študiji pri otrocih in mladostnikih, starih 1-18 let, z de novo ALL (študija MC-ASP.5/ALL) je bilo do 33. dne indukcijskega zdravljenja 10 bolnikov v skupini z zdravilom Spectrila (10,3 %) in 9 v referenčni skupini (8,9 %) pozitivnih za antiasparaginazna protitelesa vsaj v eni časovni točki.
In the study in chronic phase CML patients who could not tolerate imatinib or whose disease had stopped responding to it, 156 (49%) of the 320 patients had a major cytogenetic response after having received Tasigna for an average of 341 days (around eleven months).
V študiji kronične faze mieloične levkemije je pri 156 (49 %) od 320 bolnikov, ki niso mogli prenašati imatiniba ali pri katerih se je bolezen prenehala odzivati nanj, prišlo do pomembnega citogenetskega odziva, potem ko so prejemali zdravilo Tasigna v poprečju 341 dni (približno enajst mesecev).
In the study in metastatic disease, patients treated with Perjeta lived for longer without their disease getting worse than patients given placebo.
V študiji z bolniki z metastatskim rakom, so osebe, ki so prejemale zdravilo Perjeta, preživele dlje časa brez poslabšanja bolezni kot bolniki, ki so prejemali placebo.
In the study in metastatic pancreatic cancer, patients taking Tarceva as initial therapy survived without their disease getting worse for an average of 5.9 months, compared with 5.1 months in those taking placebo.
V študiji, ki je vključevala bolnike z metastatskim rakom trebušne slinavke, je bil pri bolnikih, ki so jemali zdravilo Tarceva kot začetno zdravljenje, čas do poslabšanja bolezni v povprečju 5,9 meseca, pri bolnikih, ki so jemali placebo, pa 5,1 meseca.
In the study in myopic choroidal neovascularisation, the average number of letters patients could read in an eye test before treatment was about 56; patients given Eylea could read on average 12 more letters after 24 weeks of treatment whereas in patients given sham injections the total number of letters they could read decreased on average by 2.
V študiji pri horoidalni neovaskularizaciji, ki jo povzroča kratkovidnost, je bilo povprečno število črk, ki so jih bolniki lahko prebrali na očesnem testu pred začetkom zdravljenja, okrog 56; bolniki, ki so prejeli zdravilo Eylea, so lahko po 24 tednih zdravljenja v povprečju prebrali 12 črk več, medtem ko se je pri bolnikih, ki so prejeli navidezno injekcijo, število črk, ki so jih lahko prebrali, v povprečju zmanjšalo za dve.
In the study in neurological surgery, TachoSil was comparable to current techniques: around 7% (25 out of 361) of patients treated with TachoSil had a leak of CSF, compared with around 8% (30 out of
V študiji nevrokirurških posegov je bilo zdravilo TachoSil primerljiv s sedanjimi tehnikami: pri približno 7 % (25 od 361) bolnikov, zdravljenih z zdravilom TachoSil, je prišlo do prepuščanja cerebrospinalne tekočine, v primerjavi s približno 8 % (30 od 365) tistimi, ki so bili zdravljeni s sedanjimi tehnikami.
In the study in newly diagnosed patients with chronic phase CML, Tasigna was more effective than imatinib at reducing the number of white blood cells containing the Philadelphia chromosome: 125 (44%) of the 282 patients taking Tasigna 300 mg twice a day and 120 (42.7%) of the 281 patients taking Tasigna 400 mg twice a day had a major molecular response compared with 63 (22.3%) of the 283 patients taking imatinib.
V študiji, v katero so bili vključeni bolnikih, pri katerih je bila kronična faza mieloične levkemije ugotovljena na novo, je bilo zdravilo Tasigna pri zmanjševanju števila belih krvnih celic, ki vsebujejo kromosom Philadelphia, učinkovitejše od imatiniba: pri 125 (44 %) od 282 bolnikov, ki so jemali zdravilo Tasigna v odmerku 300 mg dvakrat na dan, in 120 (42,7 %) od 281 bolnikov, ki so jemali zdravilo Tasigna v odmerku 400 mg dvakrat na dan, je prišlo do pomembnega molekularnega odziva v primerjavi s 63 (22,3 %) od 283 bolnikov, ki so jemali imatinib.
In the study in patients who had experienced a single attack of demyelination, the probability of developing MS over 24 months was lower for patients treated with Rebif than patients treated with placebo.
V študiji pri bolnikih z enim samim napadom demielinizacije je bila verjetnost za razvoj multiple skleroze v 24 mesecih nižja pri bolnikih, ki prejemali zdravilo Rebif v primerjavi s tistimi, ki so prejemali placebo.
In the study in patients whose disease had not responded to previous treatment, 49% of the patients whose previous treatment with both fludarabine and alemtuzumab had failed (47 out of 95) responded to treatment with Arzerra.
V študiji bolnikov, ki se niso odzvali na predhodno zdravljenje, se je na zdravljenje z zdravilom Arzerra odzvalo 49 % (47 od 95) bolnikov, pri katerih predhodno zdravljenje s fludarabinom in alemtuzumabom ni bilo uspešno.
In the study in patients with acute DVT, 2.1% (36 out of 1,731) of patients treated with Xarelto had either DVT recurrence or pulmonary embolism, compared with 3.0% (51 out of 1,718) of patients receiving enoxaparin/VKA.
V študiji pri bolnikih z akutno obliko DVT je 2,1 % bolnikov (36 bolnikov od 1 731), zdravljenih z zdravilom Xarelto, utrpelo bodisi ponovni pojav DVT ali pljučno embolijo v primerjavi s 3,0% bolnikov (51 bolnikov od 1 718), ki so prejemali enoksaparin.
In the study in patients with erectile dysfunction secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and 46 % on CIALIS 5 mg and 2.5 mg, respectively, as compared to 28 % with placebo.
V študiji pri bolnikih z erektilno disfunkcijo poleg diabetesa je bilo v povprečju pri bolnikih, zdravljenih z zdravilom CIALIS 5 mg oziroma 2,5 mg, uspešnih 41 in 46 % poskusov spolnega odnosa, v primerjavi z 28 % pri placebu.
In the study in patients with erectile dysfunction secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and 46% on tadalafil 5 mg and 2.5 mg, respectively, as compared to 28% with placebo.
V študiji pri bolnikih z erektilno disfunkcijo poleg diabetesa je bilo v povprečju pri bolnikih, zdravljenih s tadalafilom 5 mg oziroma 2,5 mg, uspešnih 41 in 46% poskusov spolnega odnosa, v primerjavi z 28% pri placebu.
In the study in patients with erectile dysfunction secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and 46% on tadalafil 5 mg and 2.5 mg, respectively, as compared to 28% with placebo.
V študiji pri bolnikih z erektilno disfunkcijo poleg diabetesa je bilo v povprečju pri bolnikih, zdravljenih z zdravilom Tadalafil Mylan 5 mg oziroma 2.5 mg, uspešnih 41 in 46% poskusov spolnega odnosa, v primerjavi z 28% pri placebu.
In the study in patients with non-transfusion-dependent thalassaemia syndromes, Exjade was shown to be more effective than placebo at reducing iron levels in the liver: in patients treated with Exjade (at a starting dose of 10 mg/kg/day) liver iron levels decreased on average by 3.8 mg per gram of liver compared with an average increase of 0.4 mg per gram of liver in patients treated with placebo.
V študiji pri bolnikih s sindromi od transfuzije neodvisne talasemije se je zdravilo Exjade izkazalo za učinkovitejše od placeba pri zmanjševanju ravni železa v jetrih: pri bolnikih, ki so jemali zdravilo Exjade (z začetnim odmerkom 10 mg/kg na dan), so se ravni železa v jetrih povprečno zmanjšale za 3,8 mg na gram jeter v primerjavi s povprečnim povečanjem za 0,4 mg na gram jeter pri bolnikih, ki so jemali placebo.
In the study in patients with non-valvular atrial fibrillation, 2.7% (188 out of 6958) of patients treated with Xarelto had either a stroke or a blood clot in a blood vessel, compared with 3.4% (241 out of 7004) of patients receiving warfarin.
V študiji pri bolnikih z atrijsko fibrilacijo brez okvare srčnih zaklopk je 2,7 % bolnikov (188 bolnikov od 6 958), zdravljenih z zdravilom Xarelto, utrpelo možgansko kap ali imelo krvni strdek v žili v primerjavi s 3,4 % bolnikov (241 bolnikov od 7 004), ki so prejemali varfarin.
In the study in patients with pulmonary embolism, 2.1% (50 out of 2,419) of patients treated with Xarelto had a recurrence of either DVT or pulmonary embolism, compared with 1.8% (44 out of 2,413) of patients receiving enoxaparin/VKA.
V študiji pri bolnikih s pljučno embolijo je 2,1 % bolnikov (50 od 2 419), zdravljenih z zdravilom Xarelto, utrpelo bodisi ponovni pojav DVT ali pljučno embolijo v primerjavi s 1,8% bolnikov (44 od 2 413), ki so prejemali enoksaparin/VKA.
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3patients), intra-tumoural bleeds (3patients) or both (1patient).
V študiji pri bolnikih z neresektabilnimi in/ali metastatskimi GIST je imelo 7 (5 %) bolnikov gastrointestinalne krvavitve CTC stopnje 3/4 (3 bolniki), intratumorske krvavitve (3 bolniki) ali obe vrsti krvavitev (1 bolnik).
In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intra- tumoural haemorrhages were reported (see section 4.8).
V študiji pri bolnikih z neoperabilnim in/ali metastatskim GIST so poročali o krvavitvah iz prebavil in iz tumorja (glejte poglavje 4.8).
In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intra- tumoural haemorrhages were reported (see section 4.8).
V študiji pri bolnikih z neresektabilnimi in/ali metastatskimi GIST so poročali tako o gastrointestinalnih kot o intratumorskih krvavitvah (glejte poglavje 4.8).
In the study in previously treated patients, those treated with Xalkori lived on average for nearly 8 months without their disease getting worse compared with 3 months in patients who were treated with either pemetrexed or docetaxel.
V študiji s predhodno zdravljenimi bolniki so tisti, ki so bili zdravljeni z zdravilom Xalkori, v povprečju živeli osem mesecev brez poslabšanja bolezni, medtem ko so bolniki, ki so bili predhodno zdravljeni s pemetreksedom ali docetakselom, brez poslabšanja bolezni živeli še tri mesece.
In the study in previously untreated patients, those treated with Xalkori lived on average for nearly 11 months without their disease getting worse compared with 7 months in patients who were treated with pemetrexed-containing therapy.
V študiji s predhodno nezdravljenimi bolniki so bolniki, ki so bili zdravljeni z zdravilom Xalkori, v povprečju živeli enajst mesecev brez poslabšanja bolezni, medtem ko so bolniki, ki so bili predhodno zdravljeni z zdravili, ki so vključevala pemetreksed, brez poslabšanja bolezni živeli še sedem mesecev.
In the study in rabbits mortality was reduced from 23% in untreated rabbits to 11% in those given 20 mg valnemulin per kg of feed, and about 8% in those given 35 mg valnemulin per kg feed.
V študiji pri kuncih se je smrtnost s 23 % pri nezdravljenih kuncih zmanjšala na 11 % pri kuncih, ki so jim dajali 20 mg valnemulina na kg krme, in na približno 8 % pri kuncih, ki so jim dajali 35 mg valnemulina na kg krme.
In the study in ROS1-positive patients, around 70% of patients (37 out of 53) responded completely or partially to treatment.
V študiji pri ROS1-pozitivnih bolnikih se je 70 % (37 od 53) bolnikov deloma ali popolnoma odzvalo na zdravljenje.
In the study in which NovoSeven was given in the home setting, 90% of the bleeding episodes were controlled effectively.
V študiji, ki je proučevala uporabo zdravila NovoSeven na domu, je bil uspešno vzpostavljen nadzor nad 90 % krvavitev.
In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus and calicivirus infection remained stable at a high level or increased slightly.
V študiji obnovitvenega cepljenja so ugotovili, da so ravni protiteles proti herpesvirusu rinotraheitisa mačk in kalicivirusu mačk ostale stabilne na visoki vrednosti ali pa so se zvišale.
In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus, calicivirus infection and feline panleucopenia remained stable at a high level or increased slightly.
V študiji obnovitvenega cepljenja je bilo ugotovljeno, da so ravni protiteles proti herpesvirusu rinotraheitisa mačk, okužbam s kalicivirusi in panleukopeniji mačk ostale stabilne na visoki ravni ali pa so se nekoliko zvišale.
In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus, calicivirus infection and feline panleucopenia remained stable at a high level or increased slightly.
V študiji obnovitvenega cepljenja so ugotovili, da so ravni protiteles proti herpesvirusu rinotraheitisa mačk, kalicivirusu mačk in virusu panlevkopenije mačk ostale stabilne na visoki vrednosti ali pa so se zvišale.
In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus, calicivirus infection, feline panleucopenia and C. felis remained stable at a high level or increased slightly.
V študiji obnovitvenega cepljenja je bilo ugotovljeno, da so ravni protiteles proti herpesvirusu rinotraheitisa mačk, okužbam s kalicivirusi, panleukopeniji mačk in C. felis ostale stabilne na visoki ravni ali pa so se nekoliko zvišale.
In the study looking at otitis media, the investigational vaccine containing the same polysaccharides as Synflorix was more effective than the comparator in preventing otitis media.
V študiji, v kateri so opazovali vnetje srednjega ušesa, je bilo raziskovalno cepivo, ki je vsebovalo enake polisaharide kot cepivo Synflorix, pri preprečevanju vnetja srednjega ušesa učinkovitejše od primerjalnega cepiva.
In the study of 160 patients, patients taking saxagliptin with metformin had a reduction of 0.6% in their HbA1c levels, compared with a reduction of 0.2% in patients taking placebo with metformin.
V študiji s 160 bolniki, se je pri tistih, ki so jemali saksagliptin skupaj z metforminom, raven HbA1c znižala za 0,6 % v primerjavi z 0,2-odstotnim znižanjem pri bolnikih, ki so jemali placebo skupaj z metforminom.
In the study of accelerated phase CML, 50 (42%) of the 119 patients had a haematological response, after having received Tasigna for an average of 202 days (around seven months).
V študiji pospešene faze te bolezni je pri 50 (42 %) od 119 bolnikov prišlo do hematološkega odziva, potem ko so prejemali zdravilo Tasigna v poprečju 202 dneva (približno sedem mesecev).
In the study of adults who had not been treated for HIV before, 79% of the patients taking Kaletra (259 out of 326) had viral loads below 400 copies/ml after 24 weeks, compared with 71% of the patients taking nelfinavir (233 out of 327).
V študiji z odraslimi bolniki, ki predhodno še niso bili zdravljeni proti okužbi z virusom HIV, je pri 79 % bolnikov (259 od 326), ki so prejemali zdravilo Kaletra, prišlo po 24 tednih do zmanjšanja virusnega bremena pod 400 kopij/ml, v primerjavi z 71 % bolnikov (233 od 327), ki so prejemali nelfinavir.
In the study of adults who had previously taken a protease inhibitor, 73% of the patients taking Kaletra (43 out of 59) had viral loads below 400 copies/ml after 16 weeks, compared with 54% of the patients taking the comparator medicines (32 out of 59).
V študiji z odraslimi bolniki, ki so predhodno prejemali zaviralca proteaze, je pri 73 % (43 od 59) bolnikov, ki so prejemali zdravilo Kaletra, prišlo po 16 tednih do zmanjšanja virusnega bremena pod 400 kopij/ml, v primerjavi s 54 % (32 od 59) bolnikov, ki so prejemali primerjalna zdravila.
In the study of Glanzmann’s thrombasthenia, treatment with NovoSeven was successful in 74% of the bleeds (42 out of 57).
Pri bolnikih z Glanzmannovo trombastenijo je študija pokazala, da je bilo zdravilo NovoSeven učinkovito v 74 % (42 od 57) krvavitev .
In the study of late-onset disease, patients had many of the same side effects, but they were seen less often than in studies of infantile- onset disease.
V študiji poznega nastopa bolezni se je pojavilo veliko istih neželenih učinkov, vendar so bili opaženi manj pogosto kot v študijah bolezni z zgodnjim nastopom.
In the study of Myocet or standard doxorubicin alone, 26% of each group responded.
V študiji zdravila Myocet ali standardnega doksorubicina kot samostojnih zdravil se je na zdravljenje odzvalo 26 % bolnic iz vsake skupine.